COPD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older
- People who currently have breathing symptoms such as shortness of breath, cough, or mucus/phlegm production
- People who have had breathing tests (spirometry) showing a type of airflow blockage that does not fully reverse with an inhaler, and/or who have signs of lung damage (emphysema) on a CT scan
- People who have known risk factors or causes linked to COPD (such as a history of smoking)
- People who have had a chest CT scan within the past 12 months before joining the study
- People who are able to understand, read, and write in Dutch
Who may not be able to join:
- People who have had a sudden worsening of COPD (a flare-up) within the 8 weeks before the study starts
- People who have other health conditions that affect speech or breathing coordination, such as neuromuscular disease, stroke, or a BMI over 40
- People who have other health conditions that affect how breathlessness sounds in speech, such as severe heart failure or scarring/inflammation of the lungs (interstitial lung disease)
- People who have other conditions affecting the lungs or airways, including but not limited to asthma or cystic fibrosis
- People who have conditions that significantly affect speech or voice quality, such as Parkinson's disease, bulbar palsy, or vocal cord paralysis
- People who have previously had a lobe of their lung surgically removed (lobectomy) or have had a certain type of lung procedure called endoscopic lung volume reduction (ELVR)
- People who are unable to complete a breathing measurement test called capnography
- People whose willingness or ability to follow the study requirements is unclear to the study investigators
- People who are currently participating in another study that involves an investigational treatment or device (participation in observation-only studies is permitted)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sami Simons, MD PhD, Maastricht University
Phone: +31 043 3876543
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
percentage of participants having moderate to severe emphysema on a chest CT (defined as > 25%); number of (non-linguistic) inhalations per syllable from sustained vowel; harmonics-to-noise-ratio from sustained vowel; vowel duration from sustained vowel; shimmer from sustained vowel; end-tidal CO2 from capnography (ETCO2); phase-2 slope from capnography (slp2); phase-2 slope from capnography (slp3)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.